OBJECTIVES: To evaluate the association between enrollment into an AIDS Drug Assistance Program (ADAP) and use of highly active antiretroviral therapy (HAART) and antihypertensive therapy. METHODS: Cross-sectional analyses of data were performed on HAART-eligible women enrolled in the California (n = 439), Illinois (n = 168), and New York (n = 487) Women's Interagency HIV Study sites. A subset of HIV-infected women with hypertension (n = 395) was also analyzed. Unadjusted and adjusted backward stepwise elimination logistic regression measured the association between demographic, behavioral, and health service factors and nonuse of HAART or antihypertensive medication. RESULTS: In adjusted analysis of HAART nonuse, women without ADAP were significantly more likely not to use HAART (odds ratio [OR], 2.4; 95% confidence interval [CI], 1.5-3.7) than women with ADAP. In adjusted analysis of antihypertensive medication nonuse, women without ADAP had an increased but not significant odds of antihypertensive medication nonuse (OR, 2.4; 95% CI, 0.93-6.0) than women with ADAP. CONCLUSIONS: Government-funded programs for prescription drug coverage such as ADAP may play an important role in how HIV-positive women access and use essential medications for chronic diseases.
OBJECTIVES: To evaluate the association between enrollment into an AIDS Drug Assistance Program (ADAP) and use of highly active antiretroviral therapy (HAART) and antihypertensive therapy. METHODS: Cross-sectional analyses of data were performed on HAART-eligible women enrolled in the California (n = 439), Illinois (n = 168), and New York (n = 487) Women's Interagency HIV Study sites. A subset of HIV-infectedwomen with hypertension (n = 395) was also analyzed. Unadjusted and adjusted backward stepwise elimination logistic regression measured the association between demographic, behavioral, and health service factors and nonuse of HAART or antihypertensive medication. RESULTS: In adjusted analysis of HAART nonuse, women without ADAP were significantly more likely not to use HAART (odds ratio [OR], 2.4; 95% confidence interval [CI], 1.5-3.7) than women with ADAP. In adjusted analysis of antihypertensive medication nonuse, women without ADAP had an increased but not significant odds of antihypertensive medication nonuse (OR, 2.4; 95% CI, 0.93-6.0) than women with ADAP. CONCLUSIONS: Government-funded programs for prescription drug coverage such as ADAP may play an important role in how HIV-positive women access and use essential medications for chronic diseases.
Authors: W E Cunningham; L E Markson; R M Andersen; S H Crystal; J A Fleishman; C Golin; A Gifford; H H Liu; T T Nakazono; S Morton; S A Bozzette; M F Shapiro; N S Wenger Journal: J Acquir Immune Defic Syndr Date: 2000-10-01 Impact factor: 3.731
Authors: R Andersen; S Bozzette; M Shapiro; P St Clair; S Morton; S Crystal; D Goldman; N Wenger; A Gifford; A Leibowitz; S Asch; S Berry; T Nakazono; K Heslin; W Cunningham Journal: Health Serv Res Date: 2000-06 Impact factor: 3.402
Authors: S E Barkan; S L Melnick; S Preston-Martin; K Weber; L A Kalish; P Miotti; M Young; R Greenblatt; H Sacks; J Feldman Journal: Epidemiology Date: 1998-03 Impact factor: 4.822
Authors: Judith A Cook; Mardge H Cohen; Dennis Grey; Lynn Kirstein; Jane Burke; Kathryn Anastos; Herminia Palacio; Jean Richardson; Tracey E Wilson; Mary Young Journal: Am J Public Health Date: 2002-01 Impact factor: 9.308
Authors: Mardge H Cohen; Judith A Cook; Dennis Grey; Mary Young; Lawrence H Hanau; Phyllis Tien; Alexandra M Levine; Tracey E Wilson Journal: Am J Public Health Date: 2004-07 Impact factor: 9.308
Authors: David B Hanna; Molly Jung; Xiaonan Xue; Kathryn Anastos; Jennifer M Cocohoba; Mardge H Cohen; Elizabeth T Golub; Nancy A Hessol; Alexandra M Levine; Tracey E Wilson; Mary A Young; Robert C Kaplan Journal: AIDS Patient Care STDS Date: 2016-10 Impact factor: 5.078
Authors: Allison M McFall; David W Dowdy; Carla E Zelaya; Kerry Murphy; Tracey E Wilson; Mary A Young; Monica Gandhi; Mardge H Cohen; Elizabeth T Golub; Keri N Althoff Journal: J Acquir Immune Defic Syndr Date: 2013-11-01 Impact factor: 3.731
Authors: Christina Ludema; Stephen R Cole; Joseph J Eron; Andrew Edmonds; G Mark Holmes; Kathryn Anastos; Jennifer Cocohoba; Mardge Cohen; Hannah L F Cooper; Elizabeth T Golub; Seble Kassaye; Deborah Konkle-Parker; Lisa Metsch; Joel Milam; Tracey E Wilson; Adaora A Adimora Journal: J Acquir Immune Defic Syndr Date: 2016-11-01 Impact factor: 3.731
Authors: Christina Ludema; Stephen R Cole; Joseph J Eron; G Mark Holmes; Kathryn Anastos; Jennifer Cocohoba; Marge H Cohen; Hannah L F Cooper; Elizabeth T Golub; Seble Kassaye; Deborah Konkle-Parker; Lisa Metsch; Joel Milam; Tracey E Wilson; Adaora A Adimora Journal: Am J Hypertens Date: 2017-06-01 Impact factor: 2.689
Authors: Nadya Belenky; Brian W Pence; Stephen R Cole; Stacie B Dusetzina; Andrew Edmonds; Jonathan Oberlander; Michael W Plankey; Adebola Adedimeji; Tracey E Wilson; Jennifer Cohen; Mardge H Cohen; Joel E Milam; Elizabeth T Golub; Adaora A Adimora Journal: Med Care Date: 2018-01 Impact factor: 3.178
Authors: Anna B Cope; Andrew Edmonds; Christina Ludema; Stephen R Cole; Joseph J Eron; Kathryn Anastos; Jennifer Cocohoba; Mardge Cohen; Igho Ofotokun; Elizabeth T Golub; Seble Kassaye; Deborah Konkle-Parker; Lisa R Metsch; Tracey E Wilson; Adaora A Adimora Journal: AIDS Behav Date: 2020-07
Authors: David B Hanna; Kate Buchacz; Kelly A Gebo; Nancy A Hessol; Michael A Horberg; Lisa P Jacobson; Gregory D Kirk; Mari M Kitahata; P Todd Korthuis; Richard D Moore; Sonia Napravnik; Pragna Patel; Michael J Silverberg; Timothy R Sterling; James H Willig; Ann Collier; Hasina Samji; Jennifer E Thorne; Keri N Althoff; Jeffrey N Martin; Benigno Rodriguez; Elizabeth A Stuart; Stephen J Gange Journal: PLoS One Date: 2013-11-18 Impact factor: 3.240